T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure

Current Cardiovascular Imaging Reports

Volumn 7, Issue 9, 2014, Pages 1-7

  Maestrini, Viviana ^a,b   Treibel, Thomas A ^a,c   White, Steven K ^a,c   Fontana, Marianna ^a,c   Moon, James C ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiac remodelling; Diffuse fibrosis; Extracellular space; Extracellular volume fraction; Heart failure; Interstitium; Intracellular space; Myocardial intracellular volume; Myocytes; T1 mapping

Indexed keywords

AMYLOID; GADOLINIUM;

AIRWAY REMODELING; AMYLOIDOSIS; AORTA STENOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CELL VOLUME; CONTRAST ENHANCEMENT; EDEMA; EXTRACELLULAR SPACE; FABRY DISEASE; FIBROSING ALVEOLITIS; FOLLOW UP; HEART FAILURE; HEART MUSCLE CELL; HEMATOCRIT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERSTITIUM; INTRACELLULAR RECORDING; INTRACELLULAR SPACE; IRON OVERLOAD; MYOCARDIAL DISEASE; MYOCARDITIS; RELAXATION TIME; REVIEW;

EID: 84906277199     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-014-9287-8     Document Type: Review

References (41)

1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360: 1418-28.
2. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61: 391-403.
3. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA: J Am Med Assoc. 2013;309: 1593-4.
4. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127: e6-245.
5. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378: 704-12.
6. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53: 557-73.
7. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89: 151-63.
8. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2003;5: 505-14.
9. Wong TC, Piehler KM, Zareba KM, et al. Myocardial damage detected by late gadolinium enhancement cardiovascular magnetic resonance is associated with subsequent hospitalization for heart failure. J Am Heart Assoc. 2013;2: e000416.
10. Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. J Am Coll Cardiol Img. 2011;4: 150-6.
11. Messroghli DR, Greiser A, Frohlich M, et al. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging: JMRI. 2007;26: 1081-6.
12. Piechnik SK, Ferreira VM, Dall'Armellina E, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1. 5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2010;12: 69.
13. Chow K, Flewitt JA, Green JD, et al. Saturation recovery single-shot acquisition (SASHA) for myocardial T mapping. Magn Reson Med. 2013. doi: 10. 1002/mrm. 24878.
14. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122: 138-44. The authors describe ECV calculation and validated the technique against histology.
15. Fontana M, White SK, Banypersad SM, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2012;14: 88.
16. Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99: 932-7.
17. Sado DM, Flett AS, Banypersad SM, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98: 1436-41.
18. Ferreira VM, Piechnik SK, Dall'Armellina E, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2012;14: 42.
19. Ugander M, Bagi PS, Oki AJ, et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. J Am Coll Cardiol Img. 2012;5: 596-603.
20. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. J Am Coll Cardiol Img. 2013;6: 488-97.
21. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6: 392-8.
22. Pedersen SF, Thrysoe SA, Robich MP, et al. Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused acute myocardial infarction. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2012;14: 59.
23. Feng Y, He T, Carpenter JP, et al. In vivo comparison of myocardial T1 with T2 and T2* in thalassaemia major. J Magn Reson Imaging: JMRI. 2013;38: 588-93.
24. Messroghli DR, Niendorf T, Schulz-Menger J, et al. T1 mapping in patients with acute myocardial infarction. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2003;5: 353-9.
25. Dall'Armellina E, Piechnik SK, Ferreira VM, et al. Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2012;14: 15.
26. Ferreira VM, Piechnik SK, Dall'armellina E, et al. T1 Mapping for the Diagnosis of Acute Myocarditis Using CMR: Comparison to T2-Weighted and Late Gadolinium Enhanced Imaging. J Am Coll Cardiol Img. 2013;6: 1048-58.
27. Thompson RB, Chow K, Khan A, et al. T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013;6: 637-45.
28. Fontana MBS, Treibel TA, Maestrini V, et al. Myocardial T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2013. doi: 10. 1016/j. jcmg. 2013. 10. 008.
29. Raman FS, Kawel-Boehm N, Gai N, et al. Modified look-locker inversion recovery T1 mapping indices: assessment of accuracy and reproducibility between magnetic resonance scanners. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2013;15: 64.
30. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52: 1574-80.
31. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001;218: 703-10.
32. White SK, Sado DM, Fontana M, et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. J Am Coll Cardiol Img. 2013;6: 955-62.
33. Schelbert EB, Testa SM, Meier CG, et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson: Off J Soc Cardiovasc Magn Reson. 2011;13: 16.
34. Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6: 34-9.
35. Ugander M, Oki AJ, Hsu LY, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33: 1268-78. The authors show that ECV can quantitatively characerize MI, atypical diffuse fibrosis and subtle myocardial abnormalities not clinically apparent on LGE images.
36. Liu CY, Liu YC, Wu C, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;62: 1280-7.
37. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126: 1206-16. ECV may predict short-term mortality as well as composite end-points in a large cohort of patients.
38. Wong TC, Piehler KM, Kang IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2013. doi: 10. 1093/eurheartj/eht193. ECV is associated with mortality and/or incident hospitalization for heart failure in diabetic individuals.
39. Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14: 63. The authors developed a fully automated method for producing a pixel-wise ECV maps for clinical use.
40. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15: 92. This document provides recomendations for T1 and ECV measurement, addressing issues such as scan type, scan aquisition, quality control, technical development and controversies in the field.
41. Flett AS, Sado DM, Quarta G, et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012;13: 819-26.